# CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

> **NCT02286726** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 56 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT02286726
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-04
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-22
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02286726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02286726, "CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02286726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*